http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-196430-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 |
| filingDate | 2005-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f548bafeda5dd74cfe4bb158f34db06f |
| publicationDate | 2008-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-196430-B1 |
| titleOfInvention | The method of producing interleukin-2 for pharmaceutical use, the composition containing interleukin-2 and sodium dodecyl sulfate, lyophilized pharmaceutical composition, aqueous pharmaceutical composition, set of pharmaceuticals, use of interleukin-2 microaggregates and sodium dodecyl sulfate, use of the composition containing interleukin-2 and sodium dodecyl sulfate, the use of the selected pharmaceutical agent, the use of interleukin-2 microaggregates and sodium dodecyl sulfate and a second pharmaceutical agent |
| abstract | A method of producing interleukin-2 for pharmaceutical use, comprising the steps of: (a) addingnsodium dodecyl sulfate (SDS) for a composition containing interleukin-2 with intramolecular disulfide bridges,nto obtain a final SDS concentration of at least 500 µg SDS per 1 mg of IL-2; (b) removing precipitated by gel filtrationncovalently linked IL-2 multimers c) partially removing SDS to reduce its concentration to formna composition that contains 95-250 µg SDS per mg of IL-2.n18. Composition containing interleukin-2 and sodium dodecyl sulfate, characterized in that it contains 95-250 μg of dodecyl sulfatensodium to 1 mg interleukin-2; interleukin-2 and sodium dodecyl sulfate are in the form of aggregates with an average hydrodynamic diameternin the range 8nm-20nm, and the composition has a specific haze (τ) of less than 1.1 cm2 / g.n33. A lyophilized pharmaceutical composition characterized in that, after reconstitution with 1.2 ml of sterile water tonthe injection contains for each milliliter: 1.1 mg of unglycosylated human des-alanyl-1-serine-125 IL-2; 50 mg of mannitol; 0.18 mgnsodium dodecyl sulfate (SDS); 0.17 mg monobasic sodium phosphate and 0.89 mg dibasic sodium phosphate to pH 7.5, withnwherein the IL-2 and SDS are aggregated such that, after reconstitution, the composition has a specific turbidity (τ) of less than 1.1 cm2 / g.n41. A kit comprising a composition as defined in any one of the preceding claims. 18 or 33 or 35 and a second pharmaceutical agentnselected from the group consisting of anti-CD20 antibody, anti-CD40 antibody, anti-Her2 antibody, anti-EGFR antibody,nanti-VEGF antibodies, anti-CD52 antibodies, anti-CD33 antibodies, H2 receptor agonists, Calmette-n-Guerin, thalidomide, lenalidomide, a proteasome inhibitor, a combination of cyclophosphamide, vincristine and prednisone; combinationncyclophosphamide, hydroxydoxorubicin, vincristine and prednisone; cytokine, interferon α, interferon γ, 5-fluorouracil, compoundnantiretroviral, tyrosine kinase inhibitor and decitabine.n45. The use of interleukin-2 microaggregates and sodium dodecyl sulfate in the manufacture of a drug for administration to a patient,nwherein the microaggregates have an average hydrodynamic diameter in the range 8nm-20nm. |
| priorityDate | 2005-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 305.